Level of serum matrix metalloproteinase-9 in patients with acute coronary syndrome in Vietnam

Authors

  • Đỗ Hữu Chí Institute of Biotechnology, Vietnam Academy of Science and Technology
  • Nguyễn Thị Minh Phương Institute of Biotechnology, Vietnam Academy of Science and Technology
  • Bùi Thị Huyền Institute of Biotechnology, Vietnam Academy of Science and Technology
  • Nguyễn Tiến Dũng Institute of Biotechnology, Vietnam Academy of Science and Technology
  • Phạm Đình Minh Institute of Biotechnology, Vietnam Academy of Science and Technology
  • Đỗ Doãn Lợi Vietnam National Heart Institute, Bach Mai Hospital, Ministry of Health
  • Nguyễn Thúy Huyền Vietnam Military Medical University, Ministry of Defence
  • Nguyễn Bích Nhi Institute of Biotechnology, Vietnam Academy of Science and Technology
  • Phan Văn Chi Institute of Biotechnology, Vietnam Academy of Science and Technology
  • Lê Thị Bích Thảo Institute of Biotechnology, Vietnam Academy of Science and Technology

DOI:

https://doi.org/10.15625/1811-4989/15/1/12315

Keywords:

Acute coronary syndrome, ELISA, human serum, logistic regression, matrix metalloproteinase-9

Abstract

Acute Coronary Syndrome (ACS) is one of the foremost causes of mortality and morbidity worldwide as well as Vietnam. ACS was evoked by rupture or erosion of atherosclerotic plaques that was divided into Non–ST-segment elevation Acute Coronary Syndrome (NSTEACS) and ST-segment elevation myocardial infarction groups (STEMI). The matrix metalloproteinase (MMPs) is an enzyme family with fucntioning in the degradation of extracellular matrix and disruption of basement membranes. Of the MMPs, MMP-9 is expressed in the atherosclerotic plaques and plays a key role in the rupture of vulnerable atherosclerotic plaques. In this work, we measured the serum MMP-9 level in 205 patients with acute coronary syndrome (including 103 of NSTE-ACS and 102 of STEMI patients) and 101 healthy participants by sandwich Elisa method. The results showed that the MMP-9 level was significantly higher in NSTE-ACS and STEMI compared to the control group (208.59 ± 100.47 ng/mL, 189.98 ± 112.81 ng/mL vs 168.50 ± 79.52 ng/mL, respectively, P=0.014). However, a logistic regression analysis indicated that the MMP-9 level was only significantly higher in patients with NSTE ACS (OR= 1.0048, CI 95%= 1.000-1.009; P= 0.018). The serum MMP-9 level is correlated with traditional risk factors such as glucose, Cholesterol and Triglyceride by multiple logistic regression analysis. Conclusion: Our study suggests that the serum MMP-9 level is significantly associated with the NSTEACS and is a potential marker for dianogsis of ACS in the Vietnamese patients

Downloads

Download data is not yet available.

Downloads

Published

2018-04-20

Issue

Section

Articles